According to MGC Pharmaceuticals publication ‘Medicinal Cannabis in Australia: Science, Regulation & Industry’ clinical trials of medicinal cannabis have produced a range of results in terms of the effectiveness of certain products on certain illnesses and conditions. For instance, there is a ‘high’ level of evidence proving the effectiveness of medicinal cannabis products for alleviation of various symptoms for conditions including: AIDS/HIV, Alzheimer’s Disease, Arthritis, Nausea and vomiting from Chemotherapy, Cancer, Diabetic peripheral neuropathy, Multiple Sclerosis, and Anxiety and Depression.
Conditions eliciting moderate evidence of effectiveness include Arthritis, Chronic pain (fibromyalgia for instance), Epilepsy, Glaucoma, Tourette Syndrome, and sleep disorders. Conditions with limited evidence of effectiveness include Schizophrenia and Inflammatory Bowel Disease. Of course, individual’s experiences vary greatly due to genetic, neurological and societal factors.
For those wishing to bypass prescription, professionals urge caution, as unregulated and illegal cannabis or derivatives can contain impurities and bacteria, with the additional preventative measure of this being illegal in Australia. Saltivex, a Nabiximol (a regulated product containing THC and CBD extracts) is available as an oral spray prescription form of medicinal cannabis.
As according to the Therapeutic Goods Administration, known side effects from medicinal cannabis can include similar symptoms from cannabis use, such as difficulty concentrating, drowsiness and dizziness, and memory loss. Saltivex is not synthetic, and is manufactured with a 1:1 TCH to CBD ratio. Saltivex, unlike other forms of medicinal cannabis is covered under some Australian health insurance policies, and it is easier to use than unrefined cannabis.
